On the chart you can see the default numbers in dynamics for Actinium Pharmaceuticals, Inc. (ATNM). Companys revenue shows the average of 0.125 M which is -0.057 % gowth. The average gross profit for the whole period is -0.035 M which is -0.016 %. The average gross profit ratio is -0.438 %. The net income growth for the company last year performance is 0.529 % which equals -45.027 % % on average for the whole company history.,
Diving into the fiscal trajectory of Actinium Pharmaceuticals, Inc., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of -0.287. In the realm of current assets, ATNM clocks in at 78.263 in the reporting currency. A significant portion of these assets, precisely 76.677, is held in cash and short-term investments. This segment shows a change of -0.296% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 0.313, if any, in the reporting currency. This indicates a difference of 3.642% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 1.572 in the reporting currency. This figure signifies a year_over_year change of -0.181%. Shareholder value, as depicted by the total shareholder equity, is valued at 36.379 in the reporting currency. The year over year change in this aspect is -0.453%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 0, with an inventory valuation of 0, and goodwill valued at 0, if any. The total intangible assets, if present, are valued at 0.
The financial landscape of Actinium Pharmaceuticals, Inc. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -6.737. The company recently extended its share capital by issuing 14.87, marking a difference of 7.692 compared to the previous year. The company's investing activities resulted in net cash usage, amounting to -153000.000 in the reporting currency. This is a shift of -0.582 from the previous year. In the same period, the company recorded 0.79, 0, and 0, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 0.26, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.
Actinium Pharmaceuticals, Inc.'s revenue saw a change of -0.921% compared with the previous period. The gross profit of ATNM is reported to be -0.71. The company's operating expenses are 51.21, showing a change of 45.759% from the last year. The expenses for depreciation and amortization are 0.79, which is a 0.130% change from the last accounting period. Operating expenses are reported to be 51.21, which shows a 45.759% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.522% year-over-year growth. The operating income is -51.92, which shows a 0.522% change when compared to the previous year. The change in the net income is 0.529%. The net income for the last year was -48.82.
